A Phase 2 interventional study of Ashwagandha and Placebo in Chemo Fog, sponsored by Sutter Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-15.
Sponsored by Sutter Health · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Chemotherapy-Related Cognitive Impairment with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Chemotherapy-Related Cognitive Impairment · United States.
Among the 18 studies in Chemotherapy-Related Cognitive Impairment with a site in United States, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 2, and was the 9th registered.
39 studies on the registry are indexed under Chemotherapy-Related Cognitive Impairment; 19 are open to participants now.
Browse Chemotherapy-Related Cognitive Impairment studies →5 of the 18 studies in Chemotherapy-Related Cognitive Impairment with a site in United States are open now. Recruiting first, the newest first:
University of California, Irvine · Sites in United States
Ages 18+ · Women only
Joseph McCollom · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Ellis Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Chemotherapy-Related Cognitive Impairment studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 1
First in 2002; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 95 across 30 interventional studies indexed under Chemotherapy-Related Cognitive Impairment.
Median enrollment 50 across the 14 interventional studies, 37 across the 4 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 18 have an industry lead sponsor. The 10 most frequent:
Sutter Health is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Sutter Health has 1 study filed under Chemotherapy-Related Cognitive Impairment — fewer than ten, so there is no comparison to draw.
2 of the studies in Chemotherapy-Related Cognitive Impairment with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06950190Phase 3Ellis MedicineEvaluating Cognitive Changes on Patients in Chemotherapy (ECCPC) | 2027-02-20 |
| NCT04520139University of California, IrvineEffect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Chemotherapy-Related Cognitive Impairment with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 1:1 randomized double blinded placebo controlled trial. • To determine if ashwagandha can improve cognitive dysfunction when compared with placebo in patients undergoing chemotherapy for cancer.
Patients are eligible if they are currently undergoing chemotherapy or treatment with chemotherapy in the past year and state that they notice thinking or memory problems. Patients will be given FACT-Cog PCI (Version 3). Patients that score less than 63, a score that reflects moderate to severe cognitive problems, are confirmed eligible. Subjects will be randomized 1:1 in blocks of 4.
Thyroid hormone testing will be conducted at baseline and at the end of week 6 for patients with a history of thyroid disease.
Patients will receive ashwagandha 350 mg po BID or placebo. The investigators and participants will be blinded to group assignment.
Endpoint testing including the FACT-Cog PCI and total score, Hopkins verbal learning test, trail making test (abstraction and executive function), and Mini Mental Status Exam (MMSE) will be administered at baseline and after 9 weeks of treatment. Six months after stopping the study, patients will receive a link to a REDCap database to complete the FACT-Cog and state whether they used ashwagandha once they completed the study.
Active study participation will be for 9 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ashwagandha
Drug: Ashwagandha
Placebo
Drug: Placebo
Ashwagandha 350 mg po BID
Placebo 350 mg po BID
FACT-Cog PCI
The Functional Assessment of Cancer Therapy - Cognition (FACT-Cog) is a 37-item questionnaire designed to assess cognitive complaints in patients with cancer. The Perceived Cognitive Impairment (PCI) subscale consists of 20 items designed to measure perceived impairment in quality of life. Scores range from 0-72 where higher scores indicate less impairment and better quality of life.
Time frame: 9 weeks
Started Jan 2023 (actual). Primary completion is estimated for Dec 2024, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ashwagandha
Chemotherapy-Related Cognitive Impairment →
Sutter Health